Iron-dextran

Bezeichnung:Iron-dextran

CAS-Nr9004-66-4

Englisch Name:Iron-dextran

CBNumberCB9139534

SummenformelFeH2O4S

Molgewicht153.92348

MOL-Datei9004-66-4.mol

Iron-dextran physikalisch-chemischer Eigenschaften

storage temp.	Room Temperature
Löslichkeit	Water (Slightly)
Aggregatzustand	solution
Farbe	Very Dark Red to Black
Wasserlöslichkeit	Iron, ~100?mg/mL in water
IARC	2B (Vol. 2, Sup 7) 1987
EPA chemische Informationen	Iron dextran (9004-66-4)

Sicherheit

Kennzeichnung gefährlicher	Xn,T
R-Sätze:	40-42/43-43-45
S-Sätze:	23-26-36/37/39-45-36-36/37-53
WGK Germany	-
RTECS-Nr.	NI2200000
Giftige Stoffe Daten	9004-66-4(Hazardous Substances Data)
Toxizität	LD50 i.v. in mice: 2240 mg Fe/kg (Beliles)

Gefahreninformationscode (GHS)

Iron-dextran Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:
R40:Verdacht auf krebserzeugende Wirkung.
R42/43:Sensibilisierung durch Einatmen und Hautkontakt möglich.
S-Sätze Betriebsanweisung:
S23:Gas/Rauch/Dampf/Aerosol nicht einatmen(geeignete Bezeichnung(en) vom Hersteller anzugeben).
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).
S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen.
Beschreibung
Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible. It is supplied as a parenteral preparation and is used as a hematinic. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1292)
Iron-Dextran is for the parenteral treatment of iron-deficiency anemia in humans and baby pigs. Can be used as a reagent.
Chemische Eigenschaften
Light to dark brown powder. Colloidal suspension of an iron-dextran complex in water. pH 5.2-6.5.
History
The therapeutic value of colloidal iron preparations was first reported in the 1950's by London and Twigg. Numerous attempts have been made to improve these iron preparations Thus dextran ([h] 0.05) is first heated with alkali, and is then neutralized in the presence of ferric chloride solution. Studies on this product have revealed that each particle consists of a central iron core, approximately 3nm diameter, surrounded by a dextran sheath of approximately 13nm diameter. The complex is visualized as a particle formed by a protective sheath of dextran attached by terminal metasaccharinic acid units to a b-FeOOH core. A solution of this complex containing 5% iron and 20% dextran (Imferon ™ ) is suitable for intramuscular and intravenous injection for treating iron deficiency anemia. The product is currently used widely for treating anemia in new-born piglets.
The use of these preparations has been re-examined in humans and a dramatic rise in hemoglobin was reported following intravenous infusion. The solution is best administered together with glucose solutions.
Verwenden
Iron-Dextran (ferric hydroxide dextran complex) may be used as an intravenous iron delivery preparation. Iron-Dextran may be used to induce iron-overload to study its effects and preventative measures.
Verwenden
Hematinic.
Trademarks
Dexferrum (Luitpold); Infed (Wat son); Proferdex (New River).
Reaktivität anzeigen
Iron-dextran is unstable at a pH of 5 and decomposes at 149-158° F. Iron-dextran may be sensitive to prolonged exposure to air.
Health Hazard
SYMPTOMS: The symptoms associated with exposure to Iron-dextran are headaches, vomiting, and dizziness.
Brandgefahr
Iron-dextran is combustible.
Clinical Use
Prophylaxis of iron deficiency anaemia (when oral treatment is ineffective or contraindicated)

Treatment of iron deficiency during ESA therapy especially if serum ferritin is very low (<50 nanograms/mL)
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Dimercaprol: avoid concomitant use.
Oral iron: reduced absorption of oral iron
Carcinogenicity
Iron dextran complex is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals.
Stoffwechsel
After intravenous infusion, iron dextran is taken up by the cells of the reticuloendothelial cells, particularly in the liver and spleen. The reticuloendothelial cells gradually separate iron from the iron-dextran complex. Most absorbed iron is bound to transferrin and transported to the bone marrow where it is incorporated into haemoglobin; the remainder is contained within the storage forms, ferritin or haemosiderin, or as myoglobin, with smaller amounts occurring in haem-containing enzymes or in plasma bound to transferrin.
Only very small amounts of iron are excreted as the majority released after the destruction of the haemoglobin molecule is re-used.

Iron-dextran Upstream-Materialien And Downstream Produkte

Iron-dextran Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

9004-66-4, Iron-dextran Verwandte Suche:

Send Inquriy